Mirae Asset Global Investments Co. Ltd. Has $615,000 Stock Holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) by 17.1% in the fourth quarter, Holdings Channel.com reports. The firm owned 40,574 shares of the company’s stock after buying an additional 5,917 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Zentalis Pharmaceuticals were worth $615,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in ZNTL. Eventide Asset Management LLC increased its position in Zentalis Pharmaceuticals by 13.6% during the 3rd quarter. Eventide Asset Management LLC now owns 7,814,039 shares of the company’s stock worth $156,750,000 after purchasing an additional 936,236 shares in the last quarter. Vanguard Group Inc. increased its position in Zentalis Pharmaceuticals by 6.2% during the 3rd quarter. Vanguard Group Inc. now owns 5,236,663 shares of the company’s stock worth $105,047,000 after purchasing an additional 307,490 shares in the last quarter. Sectoral Asset Management Inc. increased its position in Zentalis Pharmaceuticals by 65.2% during the 3rd quarter. Sectoral Asset Management Inc. now owns 386,525 shares of the company’s stock worth $7,754,000 after purchasing an additional 152,525 shares in the last quarter. Qube Research & Technologies Ltd acquired a new position in Zentalis Pharmaceuticals during the 3rd quarter worth approximately $2,836,000. Finally, TD Asset Management Inc increased its position in Zentalis Pharmaceuticals by 76.1% during the 3rd quarter. TD Asset Management Inc now owns 180,768 shares of the company’s stock worth $3,626,000 after purchasing an additional 78,140 shares in the last quarter.

Zentalis Pharmaceuticals Stock Performance

Shares of NASDAQ ZNTL opened at $10.99 on Friday. Zentalis Pharmaceuticals, Inc. has a 52-week low of $9.56 and a 52-week high of $31.46. The firm has a 50 day moving average price of $14.12 and a two-hundred day moving average price of $13.91. The stock has a market cap of $779.50 million, a P/E ratio of -2.42 and a beta of 1.73.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its quarterly earnings data on Tuesday, February 27th. The company reported ($0.83) EPS for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.09. Analysts predict that Zentalis Pharmaceuticals, Inc. will post -3.72 earnings per share for the current fiscal year.

Insider Activity

In other news, CFO Melissa B. Epperly sold 2,573 shares of the company’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $11.44, for a total value of $29,435.12. Following the sale, the chief financial officer now directly owns 451,449 shares of the company’s stock, valued at approximately $5,164,576.56. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 6.10% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on ZNTL shares. Wedbush upped their price target on shares of Zentalis Pharmaceuticals from $12.00 to $15.00 and gave the company a “neutral” rating in a research report on Wednesday, February 28th. HC Wainwright restated a “buy” rating and issued a $46.00 price target on shares of Zentalis Pharmaceuticals in a research report on Wednesday, February 28th. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $38.57.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.